#United States #Hayward #Accuryn Medical #AKI Monitoring #SmartFoley

Accuryn Medical Celebrates a Major Milestone

Accuryn Medical, a pioneering company focused on combating acute kidney injury (AKI), has recently announced a significant achievement in healthcare innovation. As of March 4, 2025, the company has successfully shipped 100,000 SmartFoley catheters across hospitals in the United States. This accomplishment is not just a numeric milestone but reflects the increasing demand for advanced renal monitoring solutions that cater to critical care environments.

Redefining Kidney Care
The SmartFoley catheter, a cornerstone of Accuryn Medical’s offerings, reimagines the traditional Foley catheter by incorporating cutting-edge sensor technology. Coupled with the Accuryn Monitoring System, this device empowers healthcare professionals by providing real-time data on key metrics such as urine output, intra-abdominal pressure, and body temperature. Such information is crucial in guiding clinical decisions, ultimately leading to enhanced patient outcomes, especially in intensive care settings.

Supporting Clinicians
Sanjay Banerjee, the CEO of Accuryn Medical, expressed his pride in the team’s achievements, emphasizing that reaching this sales milestone is a strong indicator of the value the Accuryn Monitoring System provides to clinicians. “Our system not only meets a real need within critical care facilities but also fits seamlessly into existing workflows,” he commented, highlighting the system's potential for broader applications.

Healthcare professionals often contend with prolonged hospital stays and rising costs due to infections and complications arising from manual monitoring of kidney function. The Accuryn Monitoring System aims to mitigate these challenges by automating time-intensive processes, thus allowing clinical staff to focus on providing optimal care.

The Impact of AKI
Acute kidney injury is a serious condition, with statistics indicating that nearly 42% of patients admitted to intensive care units (ICUs) face this complication. The repercussions include increased mortality rates, extended hospitalizations, and significantly greater care expenses. Moreover, even after discharge, patients with a history of kidney issues remain vulnerable to further complications.

What sets the Accuryn SmartFoley apart is its patented DrainLine Clearance technology that automates urine output measurement. This function enables healthcare providers to detect the onset of AKI well in advance of traditional methods, adhering to KDIGO guidelines. Such early detection is vital for formulating effective treatment plans and potentially improving recovery trajectories for patients.

Future Prospects
As Accuryn Medical continues to expand its reach, with systems already deployed in over 70 U.S. hospitals and trials underway in key European markets, the commitment to transforming the landscape of kidney care is clear. Through relentless innovation and a steadfast focus on clinicians’ needs, Accuryn Medical is poised to make significant strides in reducing preventable mortality and morbidity associated with AKI.

For more information about Accuryn Medical and its groundbreaking technology, interested parties can visit www.accuryn.com. With such milestones, Accuryn Medical heralds a new era in real-time renal assessment that promises not only to improve patient care but to reshape how kidney injuries are monitored and managed in hospitals.